(Total Views: 352)
Posted On: 10/10/2017 9:25:11 AM
Post# of 72446
Interesting post from the swamp by mzport:
Tuesday, 10/10/17 09:15:16 AM
Re: None
Post #
199558
of 199559 Go
This is a good example of the type of deal and that could be struck for any one of a number of the indications that fall under our three main drugs. Merck tying up with this small pharmaceutical company. It seems that KALV has maintained the upper hand as the structure of the deal appears to be very favorable and flexible to their benefit. Premarket is looking at a 100% jump in share price.
" Under the terms of the agreement, KalVista has granted to Merck certain rights including an option to acquire KVD001 through a period following completion of the Phase 2 proof-of-concept trial that KalVista intends to commence later this year. KalVista also has granted to Merck a similar option to acquire investigational orally delivered molecules for DME that KalVista will continue to develop as part of its ongoing research and development activities. As consideration for the agreement, Merck will pay to KalVista a $37 million non-refundable upfront fee. KalVista is further eligible to receive payments associated with the exercise of the options by Merck and the achievement of milestones for each program that potentially total up to $715 million. KalVista also will receive tiered royalties on net sales for therapeutic candidates commercialized under this agreement. KalVista will fund and retain control over the planned Phase 2 clinical trial of KVD001 as well as development of the investigational oral DME compounds through Phase 2, unless Merck exercises its options earlier.
In addition to the collaboration, KalVista has entered into a separate $9.1 million private placement transaction with Merck under which Merck has acquired 1,070,589 shares of KalVista, representing a 9.9% ownership stake, at a price of $8.50 per share. This private placement closed concurrent with execution of the Option Agreement. "
Go IPIX!!!
Tuesday, 10/10/17 09:15:16 AM
Re: None
Post #
199558
of 199559 Go
This is a good example of the type of deal and that could be struck for any one of a number of the indications that fall under our three main drugs. Merck tying up with this small pharmaceutical company. It seems that KALV has maintained the upper hand as the structure of the deal appears to be very favorable and flexible to their benefit. Premarket is looking at a 100% jump in share price.
" Under the terms of the agreement, KalVista has granted to Merck certain rights including an option to acquire KVD001 through a period following completion of the Phase 2 proof-of-concept trial that KalVista intends to commence later this year. KalVista also has granted to Merck a similar option to acquire investigational orally delivered molecules for DME that KalVista will continue to develop as part of its ongoing research and development activities. As consideration for the agreement, Merck will pay to KalVista a $37 million non-refundable upfront fee. KalVista is further eligible to receive payments associated with the exercise of the options by Merck and the achievement of milestones for each program that potentially total up to $715 million. KalVista also will receive tiered royalties on net sales for therapeutic candidates commercialized under this agreement. KalVista will fund and retain control over the planned Phase 2 clinical trial of KVD001 as well as development of the investigational oral DME compounds through Phase 2, unless Merck exercises its options earlier.
In addition to the collaboration, KalVista has entered into a separate $9.1 million private placement transaction with Merck under which Merck has acquired 1,070,589 shares of KalVista, representing a 9.9% ownership stake, at a price of $8.50 per share. This private placement closed concurrent with execution of the Option Agreement. "
Go IPIX!!!
(1)
(0)
